|
|
|
|
|
22.05.25 - 08:51
|
Aufschlag von 246 Prozent! Sanofi greift nach Alzheimer-Hoffnung (Der Aktionaer)
|
|
|
Trotz der Verfügbarkeit des Alzheimer-Medikaments Leqembi (Lecanemab) vom Forschungsduo Eisai respektive Biogen ist der Bedarf an Therapien zur Behandlung der Demenzform weiterhin extrem hoch. Sanofi will sich nun einen Hoffnungsträger gegen Alzheimer unter den Nagel reißen, der sich in der klinischen Entwicklungsphase befindet....
|
|
|
21.05.25 - 08:06
|
Interim Report for the period January – March 2025 (Cision)
|
|
|
Leqembi approved in the EU and billion-dollar license agreement with Bristol Myers Squibb came into effect
Events during the first quarter 2025
· FDA approved less frequent IV maintenance dosing of Leqembi® for the treatment of early Alzheimer's disease and accepted the Biologics License Application (BLA) for subcutaneous maintenance dosing of Leqembi in the US
· Leqembi sales during BioArctic's partner Eisai's fiscal year 2024 (Apr-24 – Mar-25) exceeded EUR 200 M, resulting in a EUR 10 M milestone payment to BioArctic
· The license agreement with Bristol Myers Squibb came...
|
|
|
|
|
|
|
|
|
|
|
|
|
15.05.25 - 06:01
|
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 – March 2026) (Cision)
|
|
|
Stockholm, Sweden, May 15, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 (April 2025 through March 2026), corresponding to a 73 percent growth compared to the previous year. This would generate approximately SEK 510 M in royalty to BioArctic during the same period.
Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai...
|
|
|
|
|
|
|
01.05.25 - 12:48
|
Sales of Leqembi[®] totaled 14.7 billion yen in the first quarter 2025 (Cision)
|
|
|
Stockholm, Sweden, May 1, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the first quarter 2025, in conjunction with their partner Biogen's first quarter report. In total, sales of JPY 14.7 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 101.7 million which is an increase of approximately 380 percent compared to the royalty obtained by BioArctic in Q1 2024.
BioArctic's report for the first quarter 2025 will be published on May 21 at 08:00 CET.
---
This...
|
|
|
30.04.25 - 09:30
|
MHRA to evaluate monthly intravenous maintenance dosing of Leqembi[®] for the treatment of early Alzheimer′s disease in the UK (Cision)
|
|
|
Stockholm, April 30, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) have validated and will now evaluate a proposed Marketing Authorisation Variation for monthly lecanemab dosing in the United Kingdom. Maintenance dosing is an important step forward in providing flexibility to eligible patients and healthcare professionals.
Leqembi is already approved in the UK for intravenous (IV) treatment every two weeks.[1] The proposed intravenous maintenance dosing variation application offers the...
|
|
|
|
|
16.04.25 - 12:57
|
Eisai Aktie: Am Ziel - Alzheimer-Medikament für Europa (Aktiencheck)
|
|
|
Kulmbach (www.aktiencheck.de) - Eisai-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von Eisai Co. Ltd. (ISIN: JP3160400002, WKN: 855526, Ticker-Symbol: EII, Nasdaq OTC-Symbol: ESALF) unter die Lupe.
Nach einem langen Ringen seien Biogen und der Partner Eisai in Europa endlich am Ziel. [mehr]...
|
|
|
16.04.25 - 09:54
|
Biogen und Eisai: Am Ziel – Alzheimer-Medikament für Europa (Der Aktionaer)
|
|
|
Nach einem langen Ringen sind Biogen und der Partner Eisai in Europa endlich am Ziel. Der Antikörper Lecanemab (Leqembi) wurde nach einem langen Hin und Her von der Europäischen Kommission final zugelassen. Ein Meilenstein, handelt es sich dabei um die erste zugelassene Alzheimer-Therapie überhaupt in der EU....
|
|
|
|
|
|
|
16.04.25 - 01:12
|
EU approves Leqembi® (lecanemab) for treatment of early Alzheimer′s disease (Extended information) (Cision)
|
|
|
Stockholm, April 16, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has announced that the European Commission has granted Marketing Authorization (MA) for Leqembi (lecanemab) in the European Union (EU). This is the first therapy targeting an underlying cause of Alzheimer's disease (AD) to be granted an MA in the EU. The regulatory approval in the EU entitles BioArctic to a milestone payment of EUR 20 million.
In the EU, Leqembi is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
